Treatment of breast cancer with antiestrogen: approach to medical hypophysectomy?

A. Manni, J. Trujillo, J. Brodkey, J. S. Marshall, O. H. Pearson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Tamoxifen (ICI 46474), an antiestrogen, was given to 89 selected patients with stage IV breast cancer at a dose of 20 mg orally every 12 hours. Forty-seven percent of the patients had objective tumor regression averaging 11+ months with 25 of 42 women still in remission. In the first 39 patients where the minimum follow-up period is 16 months the average duration of remission is more than 15 months with 8 of 19 patients still in remission. These results are approaching those of surgical hypophysectomy, where, in our experience the average remission lasts about 18 months. Thus, Tamoxifen is a highly effective antitumor agent and is probably the initial treatment of choice for women with hormone responsive breast cancer. Antiestrogen induced objective remissions in 5 of 19 patients who had previously responded to surgical hypophysectomy, and 5 additional patients showed no progression of disease lasting 15+ months. Estradiol and estrone were detectable in the serum of these patients whereas, prolactin and growth hormone were not detectable. Thus, antiestrogen can induce remissions in some patients in the absence of the pituitary gland, and this constitutes additional palliation and provides evidence that estrogens can directly stimulate tumor growth. Four of 7 patients who obtained remissions from Tamoxifen obtained further improvement from hypophysectomy, and 1 of 8 patients who failed to benefit from antiestrogen improved after hypophysectomy. These results suggest that prolactin and growth hormone may also play a role in stimulating tumor growth in some patients.

Original languageEnglish (US)
Pages (from-to)342-352
Number of pages11
JournalTransactions of the Association of American Physicians
Volume90
StatePublished - Dec 1 1977

Fingerprint

Hypophysectomy
Estrogen Receptor Modulators
Breast Neoplasms
Tamoxifen
Therapeutics
Prolactin
Growth Hormone
Neoplasms
Estrone
Pituitary Gland
Growth
Antineoplastic Agents
Disease Progression
Estradiol
Estrogens
Hormones

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Manni, A. ; Trujillo, J. ; Brodkey, J. ; Marshall, J. S. ; Pearson, O. H. / Treatment of breast cancer with antiestrogen : approach to medical hypophysectomy?. In: Transactions of the Association of American Physicians. 1977 ; Vol. 90. pp. 342-352.
@article{5d7d25b4aff141699425e7685a9e1466,
title = "Treatment of breast cancer with antiestrogen: approach to medical hypophysectomy?",
abstract = "Tamoxifen (ICI 46474), an antiestrogen, was given to 89 selected patients with stage IV breast cancer at a dose of 20 mg orally every 12 hours. Forty-seven percent of the patients had objective tumor regression averaging 11+ months with 25 of 42 women still in remission. In the first 39 patients where the minimum follow-up period is 16 months the average duration of remission is more than 15 months with 8 of 19 patients still in remission. These results are approaching those of surgical hypophysectomy, where, in our experience the average remission lasts about 18 months. Thus, Tamoxifen is a highly effective antitumor agent and is probably the initial treatment of choice for women with hormone responsive breast cancer. Antiestrogen induced objective remissions in 5 of 19 patients who had previously responded to surgical hypophysectomy, and 5 additional patients showed no progression of disease lasting 15+ months. Estradiol and estrone were detectable in the serum of these patients whereas, prolactin and growth hormone were not detectable. Thus, antiestrogen can induce remissions in some patients in the absence of the pituitary gland, and this constitutes additional palliation and provides evidence that estrogens can directly stimulate tumor growth. Four of 7 patients who obtained remissions from Tamoxifen obtained further improvement from hypophysectomy, and 1 of 8 patients who failed to benefit from antiestrogen improved after hypophysectomy. These results suggest that prolactin and growth hormone may also play a role in stimulating tumor growth in some patients.",
author = "A. Manni and J. Trujillo and J. Brodkey and Marshall, {J. S.} and Pearson, {O. H.}",
year = "1977",
month = "12",
day = "1",
language = "English (US)",
volume = "90",
pages = "342--352",
journal = "Transactions of the Association of American Physicians",
issn = "0066-9458",

}

Treatment of breast cancer with antiestrogen : approach to medical hypophysectomy? / Manni, A.; Trujillo, J.; Brodkey, J.; Marshall, J. S.; Pearson, O. H.

In: Transactions of the Association of American Physicians, Vol. 90, 01.12.1977, p. 342-352.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of breast cancer with antiestrogen

T2 - approach to medical hypophysectomy?

AU - Manni, A.

AU - Trujillo, J.

AU - Brodkey, J.

AU - Marshall, J. S.

AU - Pearson, O. H.

PY - 1977/12/1

Y1 - 1977/12/1

N2 - Tamoxifen (ICI 46474), an antiestrogen, was given to 89 selected patients with stage IV breast cancer at a dose of 20 mg orally every 12 hours. Forty-seven percent of the patients had objective tumor regression averaging 11+ months with 25 of 42 women still in remission. In the first 39 patients where the minimum follow-up period is 16 months the average duration of remission is more than 15 months with 8 of 19 patients still in remission. These results are approaching those of surgical hypophysectomy, where, in our experience the average remission lasts about 18 months. Thus, Tamoxifen is a highly effective antitumor agent and is probably the initial treatment of choice for women with hormone responsive breast cancer. Antiestrogen induced objective remissions in 5 of 19 patients who had previously responded to surgical hypophysectomy, and 5 additional patients showed no progression of disease lasting 15+ months. Estradiol and estrone were detectable in the serum of these patients whereas, prolactin and growth hormone were not detectable. Thus, antiestrogen can induce remissions in some patients in the absence of the pituitary gland, and this constitutes additional palliation and provides evidence that estrogens can directly stimulate tumor growth. Four of 7 patients who obtained remissions from Tamoxifen obtained further improvement from hypophysectomy, and 1 of 8 patients who failed to benefit from antiestrogen improved after hypophysectomy. These results suggest that prolactin and growth hormone may also play a role in stimulating tumor growth in some patients.

AB - Tamoxifen (ICI 46474), an antiestrogen, was given to 89 selected patients with stage IV breast cancer at a dose of 20 mg orally every 12 hours. Forty-seven percent of the patients had objective tumor regression averaging 11+ months with 25 of 42 women still in remission. In the first 39 patients where the minimum follow-up period is 16 months the average duration of remission is more than 15 months with 8 of 19 patients still in remission. These results are approaching those of surgical hypophysectomy, where, in our experience the average remission lasts about 18 months. Thus, Tamoxifen is a highly effective antitumor agent and is probably the initial treatment of choice for women with hormone responsive breast cancer. Antiestrogen induced objective remissions in 5 of 19 patients who had previously responded to surgical hypophysectomy, and 5 additional patients showed no progression of disease lasting 15+ months. Estradiol and estrone were detectable in the serum of these patients whereas, prolactin and growth hormone were not detectable. Thus, antiestrogen can induce remissions in some patients in the absence of the pituitary gland, and this constitutes additional palliation and provides evidence that estrogens can directly stimulate tumor growth. Four of 7 patients who obtained remissions from Tamoxifen obtained further improvement from hypophysectomy, and 1 of 8 patients who failed to benefit from antiestrogen improved after hypophysectomy. These results suggest that prolactin and growth hormone may also play a role in stimulating tumor growth in some patients.

UR - http://www.scopus.com/inward/record.url?scp=0017637729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017637729&partnerID=8YFLogxK

M3 - Article

C2 - 611666

AN - SCOPUS:0017637729

VL - 90

SP - 342

EP - 352

JO - Transactions of the Association of American Physicians

JF - Transactions of the Association of American Physicians

SN - 0066-9458

ER -